About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 321 record(s)
Req # A-2020-001918
Adverse Drug Reactions (ADRs). Report numbers: E2B_02900917, E2B_02494104, 000725690, E2B_02617866.Organization: Health Canada
March 2022
Req # A-2020-001945
Adverse Drug Reaction (ADR) for Berinert. Report number: E2B_ 03535699.Organization: Health Canada
March 2022
Req # A-2021-000057
Adverse Drug Reactions (ADRs) for Pneumovax 23. Report numbers: 000707681, 000707889, 000708022, 000708466, 000708722, 000709345, 000709795. ADR for Posanol. Report number: E2B_01439413. ADRs for ProQuad. Report numbers: 000700332, 000702090.Organization: Health Canada
March 2022
Req # A-2021-000101
Adverse Drug Reactions (ADRs). Report numbers: 000915847, 000924621, 000925645, 000916050, 000930241, E2B_03585355, E2B_03467325, E2B_03082149, E2B_03319613, E2B_03468383, E2B_03490062, E2B_03566008, E2B_03432729, E2B_03443245, E2B_03196985, E2B_02537605, E2B_02495846, E2B_02553233, 000727725, 000728847.Organization: Health Canada
March 2022
Req # A-2021-000130
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-100736-599.Organization: Health Canada
March 2022
Req # A-2021-000160
Adverse Drug Reactions (ADRs). Report numbers: E2B_02682772, E2B_02745394, E2B_02756657, E2B_02841254, E2B_02841149, 000732684, E2B_02928134, E2B_02966912, E2B_02951013, 000908265, 000909771, 000911716, 000912648, 000915329, 000918995, E2B_03074805, E2B_02875149, E2B_03080761, E2B_03113006, E2B_03286536.Organization: Health Canada
March 2022
Req # A-2021-000191
Adverse Drug Reactions (ADRs). Report numbers: 000926680, E2B_03172660, E2B_03480765, E2B_03480804, E2B_03490021, E2B_03494144, E2B_03537789, E2B_03585711, E2B_03526744, E2B_03541776.Organization: Health Canada
March 2022
Req # A-2021-000422
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-101786-296.Organization: Health Canada
March 2022
Req # A-2021-000431
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-100736-599.Organization: Health Canada
March 2022
Req # A-2021-000537
Adverse Drug Reaction (ADR) for ALIROCUMAB. Report number: E2B_03502076.Organization: Health Canada
March 2022